Carolinas HealthCare System

Research and Clinical Trials


Brief Description PrincipalĀ Investigator
The focus of this study is to evaluate the efficacy, safety, and tolerability of veliparib in women with previously untreated, Stage III or IV, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer. Crane, Erin King 
In the neoadjuvant cohort, to investigate the safety and tolerability of neoadjuvant nivolumab administration in the following tumor types:
?{ HPV-positive SCCHN
?{ HPV-negative SCCHN
?{ Merkel Cell Carcinoma
?{ Cervical, vaginal, or vulvar cancers
In the metastatic/recurrent cohort, to evaluate the investigator-assessed objective response rate (ORR) of nivolumab monotherapy in subjects with the following diseases:
?{ Metastatic or recurrent nasopharyngeal carcinoma (NPC)
?{ Metasta
Amin, Asim 
I. To maintain a Childhood Cancer Registry for infants, children, adolescents, and young adults with cancer.

II. To utilize clinical and biological data to help determine eligibility or stratification, based on childhood cancer disease classification schemas, for potential enrollment of research subjects onto Children's Oncology Group (COG) therapeutic clinical trials.

III. To develop a well annotated childhood cancer biobank for current and future research through the collection of biospe
Kaplan, Joel Adam 
Primary Objectives to include: PrimaryTo determine safe and biologically active Phase 2 doses (recommended Phase 2 doses [RP2D]) for JNJ-42756493 in the Part 1 Dose-Escalation Phase; and to evaluate the feasibility of treating a molecularly-defined subset of subjects with non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC), breast cancer, and all-comers with solid tumors with JNJ-42756493 at the RP2Ds (Part 3 and 4; Dose-Expansion Phases).
Secondary Objectives to include: To evalu
Chai, Seungjean 
Clinical trial to evaluate the activity and safety of PM01183 versus PLD or topotecan as control arm in patients with platinum-resistant ovarian cancer. PM01183 will be explored as single agent in the experimental arm (Arm A) versus PLD or topotecan in the control arm (Arm B). Crane, Erin King 
About Carolinas HealthCare System
Who We Are
Community Benefit
Corporate Financial Information
Diversity & Inclusion
Annual Report
Patient Links
Pay Your Bill
Hospital Pre-Registration
Patient Rights
Financial Assistance
Quality & Value Reports
Join Carolinas HealthCare System
Physician Careers

For Employees
Carolinas Connect
Connect with Us
Watch Carolinas HealthCare on YoutubeFollow Carolinas HealthCare on TwitterLike Carolinas HealthCare on FacebookContact Carolinas HealthCareJoin Carolinas HealthCare on LinkedInGo to our mobile website.